Peer-reviewed veterinary case report
Bioavailability comparison of two amoxicillin-clavulanic acid pills
By Vasuntrarak, Kananuch et al.·Published in BMC veterinary research·2025·Chulalongkorn University·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Comparative bioavailability study of two oral formulations of amoxicillin-clavulanic acid in healthy dogs.
- Species:
- dog
Plain-English summary
A study tested two different oral forms of the antibiotic amoxicillin-clavulanic acid in healthy Beagle dogs to see how well each worked. The dogs received a 250 mg tablet of either formulation A or B, and their blood was sampled to measure how much of the medication was absorbed. The results showed that formulation B was less effective than formulation A, meaning they are not interchangeable. This is important for pet owners to know when their veterinarian prescribes this medication, as the effectiveness can vary between different formulations.
People also search for: dog antibiotic effectiveness · amoxicillin-clavulanic acid for dogs · Beagle antibiotic treatment
Abstract
BACKGROUND: Amoxicillin-clavulanic acid combination (AMX-CA) is a widely used oral antibiotic for companion animals. In Thailand, various AMX-CA formulations are available. This study aimed to evaluate and compare the pharmacokinetic profiles and relative bioavailability of two AMX-CA formulations using a randomized, two-period, two-treatment crossover design in six healthy Beagle dogs. Each dog received a 250 mg AMX-CA tablet (formulation A or B) at a dosage of 20.5 ± 2.5 mg/kg, with a 7-day washout period between treatments. Blood samples were collected over a 24-h period post-administration, then AMX and CA concentrations were measured using LC-MS/MS. Bioequivalence was assessed based on the 90% confidence intervals (CI) for peak plasma concentration (C) and the area under the plasma concentration-time curve extrapolated to infinity (AUC), which required to fall within 80%-125%. RESULTS: The relative bioavailability of formulation B was 76.5% for AMX and 72.7% for CA, compared to formulation A. Only CA's Cmet the bioequivalence criteria, while the CIs for AUCand Cof AMX and AUCof CA were outside the acceptable range. CONCLUSIONS: Bioequivalence between the two formulations was not established, indicating that these formulations are not interchangeable.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/40091009/